1051 related articles for article (PubMed ID: 11209473)
21. Efficacy of sublingual coseasonal immunotherapy with a monomeric allergoid in Cupressaceae pollen allergy--preliminary data.
Ariano R; Panzani RC; Mistrello G
Eur Ann Allergy Clin Immunol; 2005 Mar; 37(3):103-8. PubMed ID: 15918297
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and tolerability of high dose sublingual immunotherapy in patients with rhinoconjunctivitis.
Worm M
Eur Ann Allergy Clin Immunol; 2006 Dec; 38(10):355-60. PubMed ID: 17274520
[TBL] [Abstract][Full Text] [Related]
23. Recent progress in allergen immunotherapy.
Nouri-Aria KT
Iran J Immunol; 2008 Mar; 5(1):1-24. PubMed ID: 18319521
[TBL] [Abstract][Full Text] [Related]
24. Sublingual immunotherapy is not always a safe alternative to subcutaneous immunotherapy.
Cochard MM; Eigenmann PA
J Allergy Clin Immunol; 2009 Aug; 124(2):378-9. PubMed ID: 19541352
[No Abstract] [Full Text] [Related]
25. Safety of sublingual immunotherapy with a monomeric allergoid in very young children.
Agostinis F; Tellarini L; Canonica GW; Falagiani P; Passalacqua G
Allergy; 2005 Jan; 60(1):133. PubMed ID: 15575951
[No Abstract] [Full Text] [Related]
26. Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children.
Ibañez MD; Kaiser F; Knecht R; Armentia A; Schöpfer H; Tholstrup B; Bufe A
Pediatr Allergy Immunol; 2007 Sep; 18(6):516-22. PubMed ID: 17680910
[TBL] [Abstract][Full Text] [Related]
27. A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen.
Rolinck-Werninghaus C; Wolf H; Liebke C; Baars JC; Lange J; Kopp MV; Hammermann J; Leupold W; Bartels P; Gruebl A; Bauer CP; Schnitker J; Wahn U; Niggemann B
Allergy; 2004 Dec; 59(12):1285-93. PubMed ID: 15507097
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis.
Dahl R; Kapp A; Colombo G; de Monchy JG; Rak S; Emminger W; Rivas MF; Ribel M; Durham SR
J Allergy Clin Immunol; 2006 Aug; 118(2):434-40. PubMed ID: 16890769
[TBL] [Abstract][Full Text] [Related]
29. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children.
Valovirta E; Jacobsen L; Ljørring C; Koivikko A; Savolainen J
Allergy; 2006 Oct; 61(10):1177-83. PubMed ID: 16942565
[TBL] [Abstract][Full Text] [Related]
30. Sublingual immunotherapy in the treatment of adult allergic rhinitis patients.
Canonica GW; Passalacqua G
Allergy; 2006; 61 Suppl 81():20-3. PubMed ID: 16792602
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy in children and adolescents with allergic rhinoconjunctivitis: a systematic review.
Röder E; Berger MY; de Groot H; van Wijk RG
Pediatr Allergy Immunol; 2008 May; 19(3):197-207. PubMed ID: 18221463
[TBL] [Abstract][Full Text] [Related]
32. Meta-analyses of specific immunotherapy trials.
Calderon MA
Drugs Today (Barc); 2008 Dec; 44 Suppl B():31-4. PubMed ID: 19221615
[No Abstract] [Full Text] [Related]
33. Multiallergen-specific immunotherapy in polysensitized patients: where are we?
Bahceciler NN; Galip N; Cobanoglu N
Immunotherapy; 2013 Feb; 5(2):183-90. PubMed ID: 23413909
[TBL] [Abstract][Full Text] [Related]
34. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.
Kopp MV; Hamelmann E; Zielen S; Kamin W; Bergmann KC; Sieder C; Stenglein S; Seyfried S; Wahn U;
Clin Exp Allergy; 2009 Feb; 39(2):271-9. PubMed ID: 19016798
[TBL] [Abstract][Full Text] [Related]
35. Future developments in sublingual immunotherapy.
Didier A
Allergy; 2006; 61 Suppl 81():29-31. PubMed ID: 16792604
[TBL] [Abstract][Full Text] [Related]
36. Double-blind, placebo-controlled evaluation of grass pollen specific immunotherapy with oral drops administered sublingually or supralingually.
Panzner P; Petrás M; Sýkora T; Lesná I
Respir Med; 2008 Sep; 102(9):1296-304. PubMed ID: 18585908
[TBL] [Abstract][Full Text] [Related]
37. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage.
Durham SR; Riis B
Allergy; 2007 Aug; 62(8):954-7. PubMed ID: 17620075
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of sublingual immunotherapy.
Scadding G; Durham S
J Asthma; 2009 May; 46(4):322-34. PubMed ID: 19484663
[TBL] [Abstract][Full Text] [Related]
39. Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule.
Colás C; Monzón S; Venturini M; Lezaun A
J Allergy Clin Immunol; 2006 Apr; 117(4):810-6. PubMed ID: 16630938
[TBL] [Abstract][Full Text] [Related]
40. Quantitative assessment of the compliance with once-daily sublingual immunotherapy in children (EASY project: evaluation of a novel SLIT formulation during a year).
Passalacqua G; Musarra A; Pecora S; Amoroso S; Antonicelli L; Cadario G; Di Gioacchino M; Lombardi C; Ridolo E; Sacerdoti G; Schiavino D; Senna G
Pediatr Allergy Immunol; 2007 Feb; 18(1):58-62. PubMed ID: 17295800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
